Table 2
ANCA in diseases other than systemic vasculitis
| Disease | ANCA |
| Cystic fibrosis | c, p or aANCA often to BPI found in 32%26 |
| Bronchogenic carcinoma | pANCA seen in non small cell lung cancer27 |
| Mycobacterial infection | aANCA correlation uncertain28 |
| Sarcoidosis | cANCA in 5%29 |
| HIV | c or pANCA in 20%, MPO or PR3 positive30 |
| Inflammatory bowel disease/Crohn's disease | p or aANCA, ulcerative colitis 60–75% and Crohn's disease 15–25%, usually lactoferrin not MPO31 |
| Primary biliary cirrhosis | pANCA in 30–40%32 33 |
| Autoimmune hepatitis | c or pANCA in 35–72%32 34 |
| Sclerosing cholangitis | pANCA often to lactoferrin in 60–75%32-34 |
| Amoebiasis | cANCA positive 97% (PR3 positive in 75%)35 |
| Post streptococcal glomerulonephritis | p or aANCA in 9% occasionally MPO positive36 |
| Chromomycosis | cANCA in 20% not to PR-337 |
| Malaria | aANCA in 50% (anti-cathepsin-G Ab)38 |
| Leprosy | c or pANCA positive in 17%39 |
| Myeloproliferative disorders | pANCA positive in 40% (MPO positive 8%)40 |
| Systemic lupus erythematosis | pANCA positive in 42%41 |
| Juvenile chronic arthritis | c or pANCA not to PR3 or MPO42 |
| Rheumatoid arthritis | pANCA positive most frequently to lactoferrin43 |
| Chronic graft versus host disease | aANCA in 17%, no antigenic specificity44 |
-
ANCA = antineutrophil cytoplasmic antibody; cANCA = cytoplasmic ANCA; pANCA = perinuclear ANCA; aANCA = atypical ANCA; MPO = myeloperoxidase, PR-3 = proteinase 3; BPI = bacterial permeability increasing protein.
